Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020GlobeNewsWire • 08/05/20
Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of SafetySeeking Alpha • 07/22/20
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in IsraelGlobeNewsWire • 06/17/20
Kamada Ltd (KMDA) CEO Amir London on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/18/20
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGsGlobeNewsWire • 03/11/20
Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 12/16/19
Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin ProductGlobeNewsWire • 12/09/19
Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in IsraelGlobeNewsWire • 12/02/19
Kamada Ltd. (KMDA) CEO Amir London on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/14/19
Kamada (KMDA) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 11/04/19
Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical JournalGlobeNewsWire • 10/29/19
Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/24/19
Kamada (KMDA) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/30/19